CTI BioPharma and Servier announced that the pivotal Phase III trial evaluating PIXUVRI combined with rituximab in comparison to gemcitabine combined with rituximab in patients with aggressive B-cell non-Hodgkin lymphoma did not meet its primary endpoint of an improvement in progression-free survival. “We are disappointed with the outcome of the PIX306 trial and will proceed to conduct a thorough review of clinical data to assess the next steps for the PIXUVRI program,” commented Adam Craig, MD, PhD, CEO of CTI BioPharma. “We would like to express our appreciation to the patients, families and investigators who participated in the study.” Results from the study will be submitted to a peer-reviewed journal for publication
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.